시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 갱년기 안면 홍조 시장 보고서(2025년)
Menopausal Hot Flashes Global Market Report 2025
상품코드 : 1824412
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,532,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,442,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,352,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

갱년기 안면 홍조 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 6.2%로 성장할 전망이며, 202억 8,000만 달러로 성장이 예측됩니다. 예측 기간의 성장은 비호르몬 요법의 진보, 개인화된 치료 접근법, 자연 요법에 대한 관심, 신경 전달 경로 조사 등에 기인할 것으로 예측됩니다. 예측 기간 주요 동향으로는 비약리학적 개입, 디지털 건강 솔루션, 신규 약제 제제, 갱년기 정밀의료, 병용 요법 등이 있습니다.

향후 5년간의 성장률 6.2%라고 하는 예측은 전회 예측으로부터 0.1%라고 하는 미감소를 반영하고 있습니다. 이 감소는 주로 미국과 타국가 간 관세의 영향 때문입니다. 관세의 상승은 영국이나 덴마크에서 공급되는 호르몬 보충요법과 비호르몬성 뉴로키닌 억제제의 비용을 밀어 올려, 갱년기 증상 관리 비용을 악화시키고, 치료 접근을 제한함으로써 미국 환자에게 부담을 강하게 할 가능성이 높습니다. 또한 상호관세와 무역 긴장 증가 및 제한 증가로 인한 세계 경제와 무역에 대한 악영향으로 그 영향이 더욱 광범위해질 것으로 보입니다.

갱년기 여성의 건강에 대한 정부의 이니셔티브는 향후 폐경 시장 성장을 가속할 것으로 예측됩니다. 갱년기 건강에 대한 정부의 이니셔티브에는 갱년기의 전환을 이해하고 질병을 피하기 위한 신규 연구에 대한 자금 제공과 약리학적, 임상적, 역학적 측면 및 예방 연구 관련 연구에 대한 지원이 포함됩니다. 여성의 건강에 대한 정부의 대처는 갱년기의 건강이나 홍조 등의 증상 관리, 위험 인자 연구, 예방, 중요한 건강 상태의 조기 진단에 의한 건강 증진에 대한 대처 등, 다양한 관심사를 대상으로 하고 있는 경우가 많습니다. 예를 들어, 2023년 1월, 호주 정부 기관인 뉴사우스웨일즈 주 정부에 따르면, 정부는 4년간(2022-2023년부터 2025-2026년까지) 4,030만 달러를 던져 심각한 갱년기 증상에 직면한 여성을 위해 최대 16개의 새로운 프로그램을 구축하기 시작했습니다. 따라서 갱년기 여성의 건강에 대한 정부의 이니셔티브는 갱년기 안면 홍조 시장 성장을 가속하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Menopausal hot flashes, also known as vasomotor symptoms, are common experiences during menopause and perimenopause. These symptoms manifest as intense bursts of heat, sweating, and heated skin in women. Hot flashes can be bothersome, causing discomfort, anxiety, and disruption of sleep.

The main types of treatment for menopausal hot flashes encompass hormonal treatment, non-hormonal treatment, and alternative treatment. Hormonal treatment involves therapy for women during the menopausal period when the body ceases to produce estrogen. This therapy typically includes the administration of medications containing female hormones to replace the declining estrogen levels. Pipeline analysis in this context involves the examination of drugs in different phases of development, including phase III drugs and phase I and II drugs. These treatments are typically made available through various distribution channels, such as retail pharmacies, online pharmacies, and hospital pharmacies. The applications of these treatments can be tailored to different age groups, including 51-55-year-old women, 46-50-year-old women, and 40-45-year-old women, depending on individual needs and circumstances.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The menopausal hot flashes market research report is one of a series of new reports from The Business Research Company that provides menopausal hot flashes market statistics, including menopausal hot flashes industry global market size, regional shares, competitors with menopausal hot flashes market share, detailed menopausal hot flashes market segments, market trends, and opportunities, and any further data you may need to thrive in the menopausal hot flashes industry. This menopausal hot flashes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The menopausal hot flashes market size has grown strongly in recent years. It will grow from $15.08 billion in 2024 to $15.92 billion in 2025 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to hormone replacement therapy, limited treatment options, awareness and education, shift in lifestyle management, alternative therapies:.

The menopausal hot flashes market size is expected to see strong growth in the next few years. It will grow to $20.28 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to advancements in non-hormonal therapies, individualized treatment approaches, focus on natural remedies, research on neurotransmitter pathways. Major trends in the forecast period include non-pharmacological interventions, digital health solutions, novel drug formulations, precision medicine in menopause, combination therapies.

The forecast of 6.2% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. patients by driving up the cost of hormone replacement therapies and non-hormonal neurokinin inhibitors sourced from the UK and Denmark, exacerbating menopausal symptom management costs and limiting treatment access. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The government's initiatives for women's health in menopause are expected to propel the growth of the menopausal hot flashes market going forward. The government's menopausal health initiatives include financing for novel studies to understand the menopausal transition and avoid illness and support for investigations of linked pharmacological, clinical, and epidemiological aspects and preventive research. Government initiatives for women's health frequently cover a wide variety of concerns, such as menopause health and the management of symptoms such as hot flashes, as well as efforts to promote health through risk factor research, prevention, and early diagnosis of significant health conditions. For instance, in January 2023, according to the Government of New South Wales, an Australia-based government agency, the government initiated $40.3 million over four years (2022-2023 to 2025-2026) to build up to 16 new programs for women facing severe menopausal symptoms. Therefore, the government's initiatives for women's health in menopause are driving the growth of the menopausal hot flashes market.

The rising healthcare expenditure is anticipated to drive the growth of the menopausal hot flashes market in the future. Healthcare expenditure refers to the total spending on healthcare goods and services over a specific period, usually at a national or regional level. Increased investment in healthcare can result in advanced treatment options, greater awareness of menopausal symptoms, enhanced research initiatives, improved access to healthcare services, alternative therapies, and better support programs. This can significantly improve the quality of life for women experiencing menopausal hot flashes by offering more effective treatments and supportive care services. For example, in May 2023, a report by the Office for National Statistics, a UK-based government department, revealed that healthcare spending in the UK increased by 5.6% from 2022 to 2023, compared to 0.9% growth in 2022. The total UK healthcare expenditure reached approximately $317.63 billion (£292 billion) in 2023. Therefore, the growing healthcare expenditure is contributing to the expansion of the menopausal hot flashes market.

The menopausal hot flashes market witnesses a rising inclination towards product innovations, constituting a significant trend. Notably, prominent entities within this market are actively introducing inventive solutions to fortify their market standing. An instance of this was observed in May 2023 when Astellas Pharma US Inc., a US-based pharmaceutical establishment, announced the FDA's approval of Veozah. This novel treatment, designed for menopause-induced hot flashes, marks the pioneering approval of a neurokinin 3 (NK3) receptor inhibitor for managing mild to severe hot flashes related to menopause. Its mechanism involves binding to and activating the NK3 receptor, integral in regulating body temperature within the brain.

Major industry players are strategically forging alliances to drive new product development initiatives and bolster their market presence. Such collaborations and partnerships in this domain serve to stimulate innovation, harness synergistic expertise, and expedite the progression and commercial launch of advanced therapies. For instance, in July 2022, Lisa Health Inc., a US-based digital health entity, entered a collaborative venture with Mayo Clinic, a US-based academic medical institution, to introduce 'Midday.' This app-based innovation caters to personalized menopausal management through the integration of digital therapeutics and artificial intelligence (AI). By leveraging intricate algorithms and sensor technology customized to individual stages and symptoms, Midday endeavors to address gaps in care, offering tailored guidance, educational resources, and strategies. Additionally, Midday provides users access to Mayo Clinic's technology platform, facilitating education on menopausal hormone treatment and aiding users in making informed decisions regarding its suitability.

In October 2022, Unified Women's Healthcare, a prominent US-based healthcare company specializing in women's healthcare treatment, successfully acquired Gennev for an undisclosed amount. Through this strategic acquisition, Unified Women's Healthcare aims to broaden its women's healthcare portfolio, with the objective of enhancing outcomes and the overall patient experience at every stage of a woman's healthcare journey. Gennev, the acquired company, is based in the United States and provides feminine care services, offering various treatments to empower women to take control of their health throughout and after the menopausal transition.

Major companies operating in the menopausal hot flashes market include Pfizer Inc., Johnson & Johnson, The Procter & Gamble Company, Merck & Co. Inc., Bayer AG, Novartis AG, AstraZeneca plc, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Eisai Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Shionogi & Co. Ltd., Gedeon Richter Plc, Lupin Limited, Hisamitsu Pharmaceutical Co. Inc., Noven Pharmaceuticals Inc., Ligand Pharmaceuticals Inc., Mithra Pharmaceuticals SA, TherapeuticsMD Inc., Theramex Ltd., Ascend Therapeutics Inc., EndoCeutics Inc., Sermonix Pharmaceuticals LLC, Ralington pharma LLP

North America was the largest region in the Menopausal Hot Flashes market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the menopausal hot flashes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the menopausal hot flashes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The menopausal hot flashes market consists of revenues earned by entities by providing estrogen therapy, and menopause hormone therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The menopausal hot flashes market also includes sales of venlafaxine, paroxetine, and escitalopram. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Menopausal Hot Flashes Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on menopausal hot flashes market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for menopausal hot flashes ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The menopausal hot flashes market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Menopausal Hot Flashes Market Characteristics

3. Menopausal Hot Flashes Market Trends And Strategies

4. Menopausal Hot Flashes Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Menopausal Hot Flashes Growth Analysis And Strategic Analysis Framework

6. Menopausal Hot Flashes Market Segmentation

7. Menopausal Hot Flashes Market Regional And Country Analysis

8. Asia-Pacific Menopausal Hot Flashes Market

9. China Menopausal Hot Flashes Market

10. India Menopausal Hot Flashes Market

11. Japan Menopausal Hot Flashes Market

12. Australia Menopausal Hot Flashes Market

13. Indonesia Menopausal Hot Flashes Market

14. South Korea Menopausal Hot Flashes Market

15. Western Europe Menopausal Hot Flashes Market

16. UK Menopausal Hot Flashes Market

17. Germany Menopausal Hot Flashes Market

18. France Menopausal Hot Flashes Market

19. Italy Menopausal Hot Flashes Market

20. Spain Menopausal Hot Flashes Market

21. Eastern Europe Menopausal Hot Flashes Market

22. Russia Menopausal Hot Flashes Market

23. North America Menopausal Hot Flashes Market

24. USA Menopausal Hot Flashes Market

25. Canada Menopausal Hot Flashes Market

26. South America Menopausal Hot Flashes Market

27. Brazil Menopausal Hot Flashes Market

28. Middle East Menopausal Hot Flashes Market

29. Africa Menopausal Hot Flashes Market

30. Menopausal Hot Flashes Market Competitive Landscape And Company Profiles

31. Menopausal Hot Flashes Market Other Major And Innovative Companies

32. Global Menopausal Hot Flashes Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Menopausal Hot Flashes Market

34. Recent Developments In The Menopausal Hot Flashes Market

35. Menopausal Hot Flashes Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기